Graybug Vision Appoints Bettina Maunz as Chief People Officer, Expanding the Company’s Executive Team
February 01 2021 - 7:30AM
Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage
biopharmaceutical company focused on developing transformative
medicines to treat chronic vision-threatening diseases of the
retina and optic nerve, today announced the appointment of Bettina
Maunz as Chief People Officer. In addition to building and leading
the human resources function for Graybug Vision, Ms. Maunz will
serve as Head of Communications and be a member of the company’s
executive team.
“We are delighted for Bettina to join Graybug as Chief People
Officer. Her leadership, culture and communications experience will
be important assets to our team,” said Frederic Guerard, PharmD,
Chief Executive Officer of Graybug Vision. “Her passion for
building high-performing teams and driving employee engagement will
be a strong contributor to our future success.”
“I am excited to be joining Graybug as its first Chief People
Officer,” stated Bettina Maunz. “I believe the company is at an
inflection point and I look forward to partnering with the
executive team in shaping Graybug’s culture as well as attracting
and retaining the right talent to fully leverage Graybug’s
potential.”
Bettina has served as a consultant to Graybug since August 2019
and played an integral role in the planning and successful
execution of the company’s IPO in September 2020. Prior to Graybug,
Bettina held the position of VP, Group Head of Enterprise
Communications at Novartis, where she led the development and
implementation of the enterprise communications strategy with a
focus on driving company-wide culture change in partnership with
the executive team and human resources department. Prior to that,
Bettina served as VP, Global Head of Communications at Alcon and
was President of the Alcon Foundation. During her tenure, she
established the Global Communications function, played a key role
in the company’s culture and business transformation, as well as
defined and executed Alcon’s corporate social responsibility
strategy partnering with leading non-profit organizations to
enhance access to quality eye care in developing markets as well as
local communities. Bettina also served in leadership positions at
CIBA Vision, Novartis Pharma and Serono International earlier in
her career.
About Graybug Vision
Graybug is a clinical-stage biopharmaceutical company focused on
developing transformative medicines for the treatment of diseases
of the retina and optic nerve. The company’s proprietary ocular
delivery technologies are designed to maintain effective drug
levels in ocular tissue for six months and potentially longer,
improving disease management, reducing healthcare burdens and
ultimately delivering better clinical outcomes. Graybug’s lead
product candidate, GB-102, a microparticle depot formulation of the
pan-vascular endothelial growth factor (VEGF) inhibitor, sunitinib
malate, targeting a six-month or longer dosing regimen, inhibits
multiple neovascular pathways for the intravitreal treatment of
retinal diseases, including wet age-related macular degeneration.
Graybug is also using its proprietary technologies to develop
GB-401, an injectable depot formulation of a beta-adrenergic
blocker prodrug, for primary open-angle glaucoma, with a dosing
regimen of once every six months or longer, and GB-103, a
longer-acting version of GB-102, designed to maintain therapeutic
drug levels in the retinal tissue for 12 months with a single
injection. Founded in 2011 on the basis of technology licensed from
the Johns Hopkins University School of Medicine, Graybug is
headquartered in Redwood City, California. For more information,
please visit www.graybug.vision.
Investor
ContactIR@graybug.vision(650) 487-2409 |
Media
Contactmedia@graybug.vision(404) 384-0067 |
Graybug Vision (NASDAQ:GRAY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Graybug Vision (NASDAQ:GRAY)
Historical Stock Chart
From Apr 2023 to Apr 2024